Atlas Trials

Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor

Clinical trial NCT01037127 · COMPLETED

Trial details

NCT number
NCT01037127
Sponsor
GlaxoSmithKline
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Cancer
Start date
2009-11-01
Primary completion
2011-07-01
Enrollment
97

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.